Impact of Influenza/RSV PCR Point-of-care Testing in the Emergency Medical Service.

Sponsor
University Hospital, Clermont-Ferrand (Other)
Overall Status
Unknown status
CT.gov ID
NCT04048369
Collaborator
(none)
431
1
2
11.4
37.7

Study Details

Study Description

Brief Summary

The purpose of the study is to compare Emergency Department patients who undergo influenza and RSV PCR testing using an FDA-approved point-of-care device (Cepheid Xpert® Xpress Flu/RSV) located in the ED, to patients who undergo influenza and RSV PCR testing at the core laboratory.

The principal purpose is to determine if the time spent in the ED is different in the group undergoing POC influenza testing compared to those undergoing laboratory-based influenza testing.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Rapid diagnosis of influenza in the emergency medical service
N/A

Detailed Description

  • This study will be conducted during the influenza's epidemic season. The start and the end of this study will be determined using national epidemic bases (national reference center for inluenza in Lyon).

  • Collection of consent of eligible patients after medical information by a senior emergency physician

  • Sampling = nasopharyngeal swabbing for all patients using usual testing or point-of-care testing

  • first arm : performing the test at the adult emergency department 24h/24

  • second arm : sending the test to the virology laboratory and realization during working hours

  • Collection of clinical data : a specific standardized questionnaire is used, as soon as the patient is included and until he leaves the emergency medical service, to collect clinical data and the time taken to take care of the patient

In order to reduce the bias of this study, it has been established :

After verification of the eligibility criteria and obtaining the written consent of the patient, a randomization procedure will be initiated for the patient. Randomization will be centralized at the DRCI of Clermont-Ferrand University Hospital. Patients will be randomly assigned to one of the study groups by means of individual block randomization. A document describing the randomization procedure will be kept confidentially in the DRCI of Clermont-Ferrand University Hospital;

  • The collection of data will be prospective.

A listing of patients opposing to the study's participation to verify that their characteristics are homogeneous to the general population The choice of the Genexpert® automaton used in the "point of care testing" arm whose principle of operation requires a minimum of manipulations (<2 minutes) and does not generate inter-operator variability Statistical analyzes will be performed with the Stata software (version 13, StataCorp, College Station). All statistical tests will be carried out at the risk of error of the first species α of 5%. Part of the analysis of the secondary endpoints should be primarily exploratory in nature. As discussed by Feise in 2002 (Feise RJ, Do 2: 8), the adjustment of the risk of error of 1st species will not be proposed systematically, but case by case in view of clinical considerations and not just statistical ones.

Continuous variables will be presented as mean and standard deviation, subject to the normality of their distribution (Shapiro-Wilk test if necessary). In case of non-normality, they will be presented as median, quartiles, and extreme values. The qualitative variables will be expressed in numbers and percentages associated. Graphic representations will be associated with these analyzes as much as possible.

Study Design

Study Type:
Interventional
Actual Enrollment :
431 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Impact Study of a Rapid Diagnosis of Influenza in the Emergency Medical Service During the 2018-2019 Epidemic Season
Actual Study Start Date :
Jan 17, 2019
Actual Primary Completion Date :
Mar 14, 2019
Anticipated Study Completion Date :
Dec 31, 2019

Arms and Interventions

Arm Intervention/Treatment
Experimental: Point-of-care testing arm

for patients randomized to the Point-of-care testing arm, nurse will perform influenza and RSV testing using an FDA-approved point-of-care device (Cepheid Xpert® Xpress Flu/RSV) in the ED, 24/24, 7/7.

Diagnostic Test: Rapid diagnosis of influenza in the emergency medical service
Comparison at the University Hospital of Clermont-Ferrand of a test performed in the Adult Emergencies Department by the nursing staff (point-of-care testing) to a test carried out in the core laboratory (classical testing).

Active Comparator: Core Lab testing arm

for patients randomized to the Core lab testing arm, influenza/RSV PCR will be performed in the core virology laboratory using Simplexa Flu A/B and RSV direct (r) assay (Diasorin), during working hours (8 am-6pm Monday to Friday, 8 am-5pm the Saturday)

Diagnostic Test: Rapid diagnosis of influenza in the emergency medical service
Comparison at the University Hospital of Clermont-Ferrand of a test performed in the Adult Emergencies Department by the nursing staff (point-of-care testing) to a test carried out in the core laboratory (classical testing).

Outcome Measures

Primary Outcome Measures

  1. Time of care in the adult emergency department [through study completion, an average of 1 week]

    Emergency care time, calculated from the time of first medical-care contact to the time of release of the adults emergency department. This time will be calculated from the data collected on the standardized questionnaire

Secondary Outcome Measures

  1. Prescription of antibiotics initiated at the adults emergency department [within 72 hours after taking care of the patient]

    nature of antibiotics

  2. Duration of the prescription of antibiotics initiated at the adults emergency department [within 72 hours after taking care of the patient]

    duration of treatment (day)

  3. Posology of antibiotics initiated at the adults emergency department [within 72 hours after taking care of the patient]

    posology (mg)

  4. Costs of antibiotics initiated at the adults emergency department [within 72 hours after taking care of the patient]

    associated costs (euros)

  5. Prescription of antiviral initiated in adults emergency department [within 72 hours after taking care of the patient]

    nature of antiviral prescription

  6. Duration of the specific antiviral prescription initiated in adults emergency department [within 72 hours after taking care of the patient]

    duration of treatment (day)

  7. Costs of specific antiviral prescription initiated in adults emergency department [within 72 hours after taking care of the patient]

    associated costs (euros)

  8. Type of prescription of imaging tests at the adults emergency department [within 72 hours after taking care of the patient]

    type of examinations related to the patient respiratory pathology

  9. Number of prescription of imaging tests at the adults emergency department [within 72 hours after taking care of the patient]

    Number of examinations related to the patient respiratory pathology

  10. Costs of the prescription of imaging tests at the adults emergency department [within 72 hours after taking care of the patient]

    Costs of examinations related to the patient respiratory pathology (euros)

  11. Type of prescription of biology examinations [within 72 hours after taking care of the patient]

    type of laboratory examinations related to respiratory pathology

  12. Number of prescription of biology examinations [within 72 hours after taking care of the patient]

    Number of laboratory examinations related to respiratory pathology

  13. Costs of prescription of biology examinations [within 72 hours after taking care of the patient]

    Costs of laboratory examinations related to respiratory pathology (euros)

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion criteria :
  • 18 years old and older

  • coming in the emergency medical service

  • during the influenza epidemic period

  • with influenza symptoms

  • whose support requires virologic confirmation

  • people having given their consent

Exclusion criteria :
  • pregnant or breast feeding women

  • patient unable to give consent

  • tutorship or curatorship or under the protection of justice

  • patient non registered in the social security system

Contacts and Locations

Locations

Site City State Country Postal Code
1 CHU de Clermont-Ferrand Clermont-Ferrand Auvergne France 63003

Sponsors and Collaborators

  • University Hospital, Clermont-Ferrand

Investigators

  • Principal Investigator: Cécile Henquell, PU-PH, University Hospital, Clermont-Ferrand

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

Responsible Party:
University Hospital, Clermont-Ferrand
ClinicalTrials.gov Identifier:
NCT04048369
Other Study ID Numbers:
  • RBHP 2018 HENQUELL
  • 2018-A02478-47
First Posted:
Aug 7, 2019
Last Update Posted:
Aug 7, 2019
Last Verified:
Jun 1, 2019
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University Hospital, Clermont-Ferrand
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 7, 2019